The 7 major acute bacterial skin and skin structure infections markets reached a value of US$ 7.1 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 14.5 Billion by 2035, exhibiting a growth rate (CAGR) of 6.68% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
US$ 7.1 Billion |
Market Forecast in 2035
|
US$ 14.5 Billion |
Market Growth Rate 2025-2035 | 6.68% |
The acute bacterial skin and skin structure infections market has been comprehensively analyzed in IMARC's new report titled "Acute Bacterial Skin and Skin Structure Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Acute bacterial skin and skin structure infections (ABSSSI) encompass a spectrum of bacterial infections involving the skin and its underlying structures. These diseases, which can be caused by a range of pathogens, with Staphylococcus aureus and Streptococcus pyogenes being the most common, manifest in various forms, including cellulitis, erysipelas, wound infections, and major abscesses. The symptoms of ABSSSI can vary in severity but typically present as localized redness, warmth, swelling, and pain. Some individuals suffering from the illness may also develop fever, chills, and swollen lymph nodes. Diagnosis of the ailment involves a combination of clinical evaluation and laboratory tests. The healthcare professionals will assess the patient's medical history, physical examination findings, and characteristic symptoms to determine the likely bacterial infection. A wound culture or a sample from the infected site might be obtained to identify the specific bacteria causing the underlying indications. Additionally, imaging studies like ultrasound or MRI may be conducted to assess the extent of tissue involvement.
The escalating incidences of bacterial illnesses in which the pathogens can invade the body through a break in the skin, such as a scratch or a cut, are primarily driving the acute bacterial skin and skin structure infections market. In addition to this, the inflating utilization of advanced medications, like lipoglycopeptides, cephalosporins, oxazolidinones, etc., to address the underlying causative factor of the illness and decrease disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of wound care therapies, as they aid in preventing infection spread and promoting faster healing, is further propelling the market growth. Apart from this, the rising usage of innovative procedures, including debridement, abscess drainage, and incision and drainage to manage severe cases of ABSSSI, is acting as another significant growth-inducing factor. These techniques, often performed in combination with antibiotic regimens, play a crucial role in reducing the infection's impact and enhancing patient outcomes. Additionally, the emerging popularity of targeted therapies, which are designed to specifically aim at certain molecules or proteins involved in the disease process, thereby ensuring more precise and effective treatment, is expected to drive the acute bacterial skin and skin structure infections market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute bacterial skin and skin structure infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute bacterial skin and skin structure infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute bacterial skin and skin structure infections market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current acute bacterial skin and skin structure infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Orbactiv (Oritavancin) | Melinta Therapeutics |
Nuzyra (Omadacycline) | Paratek Pharmaceuticals |
Dalvance (Dalbavancin) | Allergan |
Sivextro (Tedizolid) | Merck & Co |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Acute Bacterial Skin and Skin Structure Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies